2 Top Growth Stocks to Buy Right Now and Hold Forever
https://www.fool.com/investing/2024/04/28/2-top-growth-stocks-to-buy-now-and-hold-forever/?source=iedfolrf0000001
Apr 28, 2024 - These healthcare stocks can provide enviable long-term portfolio growth.
0
AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View
https://www.zacks.com/stock/news/2263588/abbvie-abbv-beats-on-q1-earnings-sales-ups-24-eps-view?cid=CS-ZC-FT-analyst_blog|earnings_article-2263588
Apr 26, 2024 - AbbVie's (ABBV) first-quarter earnings and sales beat estimates. Management hikes the EPS guidance on the back of encouraging Skyrizi product sales.
0
Are You Looking for a High-Growth Dividend Stock?
https://www.zacks.com/stock/news/2263489/are-you-looking-for-a-high-growth-dividend-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_5-2263489
Apr 26, 2024 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
0
Top Stock Reports for NVIDIA, Alphabet & Johnson & Johnson
https://www.zacks.com/commentary/2257574/top-stock-reports-for-nvidia-alphabet-johnson-johnson?cid=CS-ZC-FT-research_daily-2257574
Apr 18, 2024 - Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Alphabet Inc. (GOOGL) and Johnson & Johnson (JNJ).
0
J&J (JNJ) Q1 Earnings Beat Estimates, Sales Miss, MedTech Soft
https://www.zacks.com/stock/news/2256185/j-j-jnj-q1-earnings-beat-estimates-sales-miss-medtech-soft?cid=CS-ZC-FT-analyst_blog|earnings_article-2256185
Apr 16, 2024 - J&J (JNJ) beats estimates for first-quarter earnings but misses the same for sales. It tightens its sales and earnings growth expectations for 2024.
0
Housing Numbers Shrink as Q1 Earnings Heat Up: BAC, JNJ, UNH
https://www.zacks.com/stock/news/2256163/housing-numbers-shrink-as-q1-earnings-heat-up-bac-jnj-unh?cid=CS-ZC-FT-ahead_of_wall_street-2256163
Apr 16, 2024 - Both Housing Starts and Building Permits missed expectations, while BofA, J&J and UnitedHealth all beat on earnings.
0
JNJ Q1 earnings preview: A lot of moving factors expected to bring in-line results
https://seekingalpha.com/news/4089736-jnj-q1-earnings-preview-a-lot-of-moving-factors-expected-to-bring-in-line-results?source=feed_sector_healthcare
Apr 15, 2024 - Johnson & Johnson (JNJ) is set to announce Q1 earnings results, and analysts expect a profit of $2.65 (-1.1% Y/Y) on revenue of $21.39B (-13.4% Y/Y).
0
3 Quarterly Releases to Watch Next Week
https://www.zacks.com/stock/news/2254814/3-quarterly-releases-to-watch-next-week?cid=CS-ZC-FT-stocks_in_the_news-2254814
Apr 12, 2024 - Earnings season is always an exciting time for investors, with companies finally revealing what's transpired behind closed doors. And concerning next week's docket, these three notable companies are scheduled to report.
0
Pharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News
https://www.zacks.com/stock/news/2254409/pharma-stock-roundup-jnj-to-buy-shockwave-medical-other-pipeline-regulatory-news?cid=CS-ZC-FT-analyst_blog|stock_roundup-2254409
Apr 12, 2024 - J&J (JNJ) is set to buy Shockwave Medical (SWAV). FDA approves AstraZeneca's (AZN) Enhertu for metastatic HER2-positive solid tumors.
0
Unlocking Q1 Potential of Johnson & Johnson (JNJ): Exploring Wall Street Estimates for Key Metrics
https://www.zacks.com/stock/news/2253845/unlocking-q1-potential-of-johnson-johnson-jnj-exploring-wall-street-estimates-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2253845
Apr 11, 2024 - Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Johnson & Johnson (JNJ), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.
0
Page 1>